Dargestellt werden die Ergebnisse einer randomisierten Studie bei 150 Patientinnen, die entweder mit 6 Zyklen Adriamycin (40 mg/m2) und Cyclophosphamid (500 mg/m2) behandelt wurden oder einer Kombination aus Adriamycin (40 mg/m2) und Cis-Platin (50 mg/m2) oder einer Kombination im Rahmen eines Wechselschemas: Adriamycin (40 mg/m2, Tag 1), Cis-Platin (100 mg/m2, Tag 2), Vincristin (1,4 mg/ m2, Tag 28), Cyclophosphamid (1500 mg/m2, Tag 25), Methotrexat (1000 mg, Tag 56) (insgesamt zwei Zyklen). Die mittleren Überlebenszeiten waren am längsten beim Wechselschema (19,6 Monate). Am deutlichsten profitierten die Patienten mit hochdifferenzierten Tumoren von dieser Art von Chemotherapie: mittlere Überlebenszeit 26,3 Monate gegenüber 17,6 Monaten.

Keywords:
Ovarialkarzinom, Chemotherapie, Randomisierung, Überlebens-raten
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.